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Over the last two centuries, there has been a significant increase in average lifespan expectancy in
the developed world. One unambiguous clinical implication of getting older is the risk of experien-
cing age-related diseases including various cancers, dementia, type-2 diabetes, cataracts and
osteoporosis. Historically, the ageing process and its consequences were thought to be intractable.
However, over the last two decades or so, a wealth of empirical data has been generated which
demonstrates that longevity in model organisms can be extended through the manipulation of
individual genes. In particular, many pathological conditions associated with the ageing process
in model organisms, and importantly conserved from nematodes to humans, are attenuated in
long-lived genetic mutants. For example, several long-lived genetic mouse models show attenuation
in age-related cognitive decline, adiposity, cancer and glucose intolerance. Therefore, these long-
lived mice enjoy a longer period without suffering the various sequelae of ageing. The greatest
challenge in the biology of ageing is to now identify the mechanisms underlying increased healthy
lifespan in these model organisms. Given that the elderly are making up an increasingly greater
proportion of society, this focused approach in model organisms should help identify tractable
interventions that can ultimately be translated to humans.
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The last 200 years has seen an astonishing increase in
human life expectancy in the developed world, with an
estimated 30 years added to average life expectancy
since the turn of the twentieth century [1]. This
increase has been achieved through factors including
better diet, cleaner water and significantly improved
preventative medicine and palliative care [2]. The
elderly are therefore making up a significantly greater
proportion of the population, particularly when allied
to low fertility and immigration [1]. Recent projections
suggest that approximately 1.6 per cent of the UK
population, compared with the current approximately
0.7 per cent, will be over 90 years of age by 2020
[3]. This means that if current trends continue, then
the majority of babies born in the UK since 2000
will celebrate their 100th birthday [1]. These rapidly
altering demographic profiles will have enormous
social, economic and ethical implications because
ageing is inexorably linked to physiological decline,
loss of independence and decreased quality of life
[4]. In particular, the prevalence of cardiovascular
disease, dementia, cancer, sarcopaenia, osteoporosis,
osteoarthritis and type-2 diabetes all increase
significantly with advancing age [4–6].r for correspondence (d.withers@imperial.ac.uk).
tribution of 15 to a Discussion Meeting Issue ‘The new
of ageing’.
99Obvious practical, ethical and economic obstacles
exist to longitudinal studies investigating the determi-
nants of human lifespan. Therefore, much effort in
the biology of ageing has employed model organisms
like yeast, the nematode worm Caenorhabditis elegans,
the fruitfly Drosophila melanogaster and the mouse
[2,7–9]. While it has been established for over 70
years that dietary restriction (DR) extends lifespan in
many organisms [10–12], it has only been more
recently that ageing and lifespan have been shown to
be modulated by genetic factors [2,13–15]. Further-
more, many age-related pathophysiological processes
relevant to the diseases of ageing in humans can be
modelled in such organisms.
Specific mutations in the insulin/insulin-like growth
factor (IGF) signalling (IIS) pathway extend lifespan
in model organisms [7–9,13,16–19]. Polymorphisms
in several IIS and growth hormone (GH)-related
genes correlate with human longevity [20–22], and
attenuated IIS may underlie the long life of GH/GH
receptor-deficient dwarf mice (e.g. Ames (Prop1df/df),
Snell (Pit1dw/dw), Little (Ghrhrlit/lit), growth hormone
receptor knockout (GHR-KO) [23]). The target of
rapamycin (TOR) pathway also plays a key and con-
served role in longevity control [24–29]. It is clear
that understanding how exactly the IIS, GH and
mTOR signalling pathways interact with one another
to increase lifespan and healthspan is a key challenge
to future research.This journal is # 2011 The Royal Society
Table 1. Attenuated ageing-related decline in various phenotypic parameters in genetic mouse models of healthy ageing.
(Long-lived genetic model and primary reference. 1, Homozygous ribosomal protein S6 kinase 1 knockout [29]; 2,
homozygous insulin receptor substrate 1 knockout [19]; 3, homozygous fat-specific insulin receptor knockout [16]; 4,
heterozygous insulin receptor substrate 2 knockout ([44], but see also [45]); 5, heterozygous insulin-like growth factor 1
receptor knockout [46]; 6, mutation of Prop1df/df [122]; 7, mutation of Pit1dw/dw [41]; 8, homozygous growth hormone
receptor (Laron) knockout [123]; 9, homozygous regulatory subunit of protein kinase A knockout [48]; 10, combined
telomerase reverse transcriptase and p53, p16 and p19ARF transgenic [50]; 11, homozygous pregnancy-associated plasma
protein A knockout [93]; 12, homozygous macrophage migration inhibitory factor knockout [94]; 13, homozygous type 5
adenylyl cyclase knockout [68]; 14, mitochondrial targeted catalase transgenic [77]; 15, heterozygous glutathione peroxidase
4 knockout [74]; 16, metallothionein-IIa transgenic [79]; 17, homozygous mammalian proto-oncogene 66K knockout [80].)
ref. mouse model
phenotypic parameter
metabolism cognition bone eye heart cancer immunity
1 S6K12/2 þ þ þ þ
2 Irs12/2 þ þ þ þ
3 FIRKO þ
4 Irs2þ/2 þ
5 Igf1rþ/2 þ
6 Ames þ þ þ
7 Snell þ þ þ þ
8 GHR-KO þ þ þ þ þ
9 RIIb þ þ þ
10 Sp53/Sp16/SArf/TgTert þ þ þ
11 PAPP-A-KO þ þ
12 MIF-KO þ
13 AC5 KO þ þ
14 MCAT þ þ þ
15 Gpx4þ/2 þ
16 MT þ
17 p66sch2/2 þ
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is to identify what underpins ageing in order to gener-
ate interventions that attenuate age-related pathology
and consequently improve healthy lifespan in
humans. Therefore, model organism studies that
show both extended lifespan and improved health
over this long life are crucial if we hope to achieve
this. This review will therefore examine those studies
of genetically modified mice demonstrating evidence
of extended healthy lifespan through the positive
effects on age-sensitive biomarkers and/or resistance
to age-related pathology (table 1). Our approach is
to describe in turn the various pathophysiological pro-
cesses and diseases relevant to ageing in humans that
are ameliorated in long-lived genetic mice. However,
it should be noted that in many cases a limited
number of pathologies have been examined, with rela-
tively few long-lived mutants having undergone
detailed examination in a broad range of disease
parameters.2. MUTATIONS IN INDIVIDUAL GENES THAT
EXTEND HEALTHY LIFESPAN IN MAMMALS
(a) Maintenance of a youthful metabolic
profile in long-lived mice
Ageing in humans is associated with greater adiposity,
particularly visceral fat, higher body mass index and a
significant loss in lean mass [30–32]. Commonly
associated with these age-related changes in body
composition are impairments in glucose tolerance
and insulin sensitivity. Elevated adiposity and insulinPhil. Trans. R. Soc. B (2011)resistance are significant risk factors for type-2 dia-
betes, coronary heart disease and stroke. In addition,
insulin resistance is linked to higher colon, liver and
pancreatic cancer incidence [33], more aggressive
breast cancer tumours [34] and Alzheimer’s disease
(AD) development [35].
The most widely studied phenotypic parameters in
long-lived mice are those associated with body compo-
sition and glucose/insulin homeostasis. It is well
established that long-lived GH/GH receptor dwarf
mice are highly insulin sensitive [36–38]. Indeed, the
absence of lifespan extension in GHR-KOmice follow-
ing DR [36] or intermittent fasting [39] is suggested
to be because these dietary interventions cannot
further increase insulin sensitivity in these animals
[40]. However, long-lived Snell dwarf mice are obese
and hyperleptinaemic in old age [41], and have
unaltered fasting (3–6 h) insulin and glucose levels
relative to control mice at 20–23 months of age
[41,42]. Percentage fat mass, normalized to total
body mass, was also elevated in GHR-KO mice over
a 2 year period relative to controls, with the increased
adiposity more apparent in males [43].
Long-lived fat-specific insulin receptor knockout
(FIRKO) mice are lean, have reduced total-body tri-
glyceride levels and show resistance to age-related
deterioration in glucose tolerance compared with
wild-type (WT) controls [16]. Insulin receptor sub-
strates 1 and 2 are key intracellular effectors of the
IIS receptors [19]. Mice heterozygote for insulin
receptor substrate 2 (Irs2þ/2) have been described as
long-lived in one study [44], but not in another despite
Review. Extended healthy lifespan in mammals C. Selman & D. J. Withers 101
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male and female Irs2þ/2 mice were significantly
more insulin sensitive at approximately 22 months of
age relative to controls in the earlier study, despite
no differences observed between genotypes at two
months of age [44]. Reportedly, long-lived female
mice heterozygote for the IGF-1 receptor (Igf1rþ/2)
( [46], but see also [47]) are also slightly more glucose
tolerant compared with control animals [46]. Recently,
we have shown that 600-day-old female mice null for
ribosomal protein S6 kinase 1 (S6K12/2), a down-
stream effector of mTOR signalling and IIS, are
lean, hypoleptinaemic, glucose tolerant and insulin
sensitive (assessed by the updated homeostasis
model, HOMA2; [29]). These improvements are
despite S6K12/2 mice being glucose intolerant at
eight weeks of age [29].
Mice null for RIIb, a regulatory subunit of protein
kinase A, are long-lived, and resistant to both age-
related obesity and hyperleptinaemia [48]. These
mice also have lower fasting blood glucose levels at
24 months of age compared with WT littermates
[48]. Male RIIb mutants were more insulin sensitive
at young (two to five months) and old (18 months)
ages relative to controls, although young females
were not [48]. Studies examining the role of the cellu-
lar reverse transcriptase telomerase (TERT) during
ageing have been complicated by the cancer-
promoting effects of telomerase [49]. However,
over-expression of Tert in the background of enhanced
cancer resistance (enhanced expression of p53, p16
and p19ARF) increased lifespan in Sp53/Sp16/SArf/
TgTert transgenic mice [50]. These animals were also
protected against age-related deteriorations in glucose
tolerance between 30 and 76 weeks of age [50].
However, several other studies demonstrate that
insulin sensitivity per se is not a prerequisite for a
long and healthy lifespan. For example, long-lived
female insulin receptor substrate 1 null (Irs12/2)
mice are both insulin and IGF-1 resistant at 450
days of age [19]. However, remarkably, these animals
are protected against an age-related deterioration in
glucose tolerance seen in WT animals because of life-
long beta-cell compensation and associated
hyperinsulinaemia [19]. It should also be noted that
despite this insulin-resistant phenotype, Irs12/2 mice
are lean and hypoleptinaemic at 450 days and 700
days of age [19]. Long-lived heterozygote brain-
specific IGF-1 receptor knockout mice
(bIGF1RKOþ/2) had greater adiposity, hyperleptinae-
mia and impaired glucose tolerance at 10 months of
age compared with WT mice [18]. Insulin resistance
and glucose intolerance were also observed in
long-lived brain-specific IRS2 heterozygote and
homozygote (bIrs2þ/2, bIrs22/2) mice [44]. Finally,
mice with over-expression of Klotho, a single-pass
transmembrane protein, are long-lived but insulin
and IGF-1 resistant [51].(b) Preserved cognitive and motor functions in
long-lived mice
Age itself is the greatest risk factor for cognitive decline
and dementia [5]. Brain-related pathologies will havePhil. Trans. R. Soc. B (2011)increasingly important implications to healthcare, gov-
ernmental policy and society, given that recent
estimates predict that AD cases in the USA alone
will rise from 377 000 cases in 1995 to around one
million by 2050 [52].
Undoubtedly, the best studied long-lived mice with
regard to cognitive function and ageing are the GH/
GH receptor dwarfs, with several studies indicating
preserved cognitive function in these mice at old age
[53–55]. For example, old (17–20 months) GHR-
KO and Ames mice (19–21 months) had improved
learning and memory compared with age-matched
WT controls [54,55]. Exactly why this is the case
is currently unknown, but intriguingly Ames mice
have been shown to have increased hippocampal
neurogenesis in adulthood [56,57].
Several other studies suggest that delayed age-
related cognitive decline exists in long-lived mice.
For example, female Irs12/2 mice at 450 days of age
showed better motor/neurological function, as
assessed by forced motor activity performance on a
rotating rod (rotarod) apparatus, compared with
WT mice [19]. Importantly, no improvement was
seen in young (80-day-old) Irs12/2 mice, suggesting
that the better rotarod performance in old age was
not due to the dwarf phenotype. An enhancement
in rotarod performance was also demonstrated
in female S6K12/2 mice at 600 days of age [29]. In
addition, these mice had enhanced overall general
activity and exploratory drive performance during
open-field testing at this age [29]. Sp53/Sp16/SArf/TgTert
mice at approximately 12 months of age also demon-
strated better neuromuscular coordination during a
tightrope test [50], and bIrs2þ/2 and bIrs22/2 mice were
significantly more active than controls at 22 months of
age [44].
Long-lived mice also appear more resistant to the
sequelae of neurodegenerative conditions such as AD.
For example, hippocampal slices from adult Ames
mice are significantly more resistant to b-amyloid
(Ab) toxicity compared with controls [58]. AD is
associated with altered neuronal insulin signalling
[59], and several studies have investigated the effect of
altered insulin signalling on AD progression. Mice
expressing the Swedish mutation of amyloid precursor
protein (APPSW, Tg2576) and crossed with long-lived
bIGF1RKOþ/2 mice [18] were rescued from APPSW-
induced early mortality and had significantly reduced
Ab accumulation at 60 weeks of age [59]. In addition,
global IRS-2 deficiency in this AD model completely
reversed early mortality and delayed Ab accumulation
[59]. In agreement, global IRS2 deficiency in APPSW
mice ameliorated Ab pathology and improved several
behavioural parameters despite increasing tau phos-
phorylation [60]. Interestingly, this is despite Irs22/2
mice of both sexes being significantly short-lived [19].
Mice expressing two AD-linked transgenes and crossed
with Igf1rþ/2 mice [46] were protected against several
AD-related pathologies and impaired cognitive func-
tion [61]. Rapamycin, an inhibitor of the mTOR
pathway, treatment significantly increases lifespan in
mice [25] andwas recently shown to attenuate cognitive
deficits, Ab pathology and tau pathology in two
different AD mouse models [62,63].
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Osteoporosis, which clinically presents as reduced
bone mass and altered bone structure, is a significant
public health issue. For example, osteoporosis-related
fractures, particularly hip fractures, are a major cause
of morbidity and mortality in humans [64]. Clinical
studies also suggest that there is overlap between several
common disease mechanisms underlying osteoporo-
sis and cardiovascular disease, including chronic
inflammation, insulin resistance and obesity [65].
Mice also are prone to significant losses in bone
volume with advancing age (e.g. [66]). Several studies
examining long-lived mice have used a cross-sectional
approach to show simultaneous preservation of bone
function and quality with age. We have demonstrated,
using micro-computed tomography, that female
Irs12/2 mice at 450 and 700 days of age are resistant
to age-related bone dysfunction [19]. Irs12/2 mice
had greater cancellous bone volume, increased trabe-
cular number and reduced trabecular separation
compared with age-matched controls. Interestingly,
this preservation in bone quality during ageing was
seen despite young Irs12/2 mice being osteopenic
[67]. Furthermore, using the same methodology, we
recently showed that 600-day-old female S6K12/2
mice also had greater tibial bone volume and trabecu-
lar number compared with age-matched WT controls
[29]. A preservation in bone volume with age was
also reported in mice lacking type 5 adenylyl cyclase
(AC5 KO), a key catalytic enzyme in the synthesis of
cyclic adenosine monophosphate from adenosine tri-
phosphate [68]. Female AC5 KO mice at 23 months
of age had greater femoral bone density and calcifica-
tion, less evidence of healing stress fractures and
improved bone strength compared with controls
[68]. Interestingly, tail tendons from young (four to
eight months) and old (16–19 months) Snell mice
are more resistant to urea-induced collagen denatur-
ing, and Snell mice are protected against articular
ageing and osteoarthritis [41,69]. Preservation of skel-
etal function during ageing is therefore often seen in
long-lived mouse models.(d) Attenuated visual deterioration in
long-lived mice
Visual impairment and visual loss caused by several
pathologies including macular degeneration, glaucoma
and cataracts increase significantly in humans with
advancing age [70]. These visual impairments may
also exacerbate additional age-related pathologies
including metabolic dysfunction, cardiovascular dis-
ease, insomnia, depression and impaired cognition
through disruption in circadian photoreception [71].
Mice show comparable age-related increases in cat-
aracts to humans, with similar regions of the lens
affected. For example, C57BL/6 mice display a
highly significant increase in the degree of cataract
severity between six and 28 months of age [72].
Using a slit lamp protocol, it has been shown that
both GHR-KO mice [72] and Snell dwarf mice [73]
are resistant to age-related cataracts, with no differ-
ences in cataract levels relative to WT controls
reported in GHR-KO mice at six months of age [72].Phil. Trans. R. Soc. B (2011)However, delayed cataract formation does not appear
to be universal among long-lived mutant mice, as no
difference was reported between long-lived glutathione
peroxidase 4 heterozygous knockout mice (Gpx4þ/2)
and controls at 25 months of age [74].(e) Improved cardiac function in long-lived mice
Cardiovascular disease is a primary cause of mortality
in humans worldwide, with its risk increasing signifi-
cantly with advancing age [75]. Cardiovascular
disease per se is not thought to be a prominent cause
of mortality in most laboratory mouse strains. How-
ever, many of the age-related deteriorations in
cardiovascular function observed in humans are also
observed in mice [76]. Consequently, there is good
evidence that aspects of cardiovascular ageing are
significantly attenuated in long-lived mice.
It has been demonstrated that AC5 KO mice, for
example, are resistant to age-related myocardial fibro-
sis and left ventricular (LV) hypertrophy [68]. These
mice also have reduced cardiac apoptosis and smaller
myocyte cross-sectional area at 20–30 months of age
compared with WT mice. Male RIIb null mice have
preserved cardiac function and less evidence of LV
hypertrophy at 24 months of age [48]. Long-lived
mice over-expressing human catalase within their
mitochondria (MCAT mice) [77] were also highly
resistant to a range of cardiac-associated pathologies,
including arteriosclerosis, cardiomyopathy, impaired
diastolic function and LV hypertrophy at 20–25
months of age [76,77]. Interestingly, age-dependent car-
diomyopathy in mice carrying a homozygous mutation
in the exonuclease-encoding domain of mitochondrial
polymerase gamma (Polgm/m mice) was ameliorated
when Polgm/m mice were crossed with MCAT mice
[78]. Transgenic mice over-expressing human metal-
lothionein-IIa, a heavy metal-binding antioxidant, in
cardiac tissue are long-lived and protected against both
age-related diastolic dysfunction and decreased cardiac
contractile reserve capacity [79]. Long-lived mice null
for the cytoplasmic adaptor protein p66shc (p66shc2/2)
are long-lived [80] and resistant to age-dependent reac-
tive oxygen species-mediated endothelial dysfunction
[81]. p66shc2/2 mice were protected against angiotensin
II-induced LV hypertrophy, associated cardiomyocyte
and endothelial cell apoptosis [82]. Long-lived mice
null for either pregnancy-associated plasma protein
A (PAPP-A-KO) [83], a metalloproteinase that degrades
IGF-bindingproteins, or p66shc [84] areprotected against
high fat diet-induced atherosclerosis when maintained in
an apolipoprotein E-deficient (ApoE) background.(f) Protection against cancer in long-lived mice
Many cancers, including breast, prostate and colorec-
tal, increase with advancing age, with the vast majority
of cancer cases seen in people over 60 years of age
[85]. The risk of mortality from cancer also increases
in an age-dependent manner [85,86], although both
incidence and mortality rate apparently plateau and
subsequently decline after 90 years of age [86].
Cancer is the primary cause of death in most mouse
strains, although tumour type appears highly strain
specific [87]. For example, the C57BL/6 strain
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prone to lymphosarcoma [74,88]. Significant effort
has focused on whether interventions that extend life-
span impact on cancer incidence and progression, with
most studies examining end of life pathology.
Several studies have investigated whether long-lived
GH/GH receptor-deficient dwarf mice are protected
against cancer [89,90]. In Ames dwarfs, age-related
neoplastic disease was delayed and adenocarcinoma
severity reduced despite the percentage of tumour-
bearing mice at death being similar to WT mice
[91]. However, tumour burden (the number of differ-
ent tumours) in Ames mice was similar to controls
[91]. In contrast, Snell dwarfs had significantly
reduced age-related tumour burdens [89] and a non-
significant trend (p ¼ 0.06) for reduced lymphoma
and mammary adenocarcinoma [73]. GHR-KO mice
also had decreased tumour incidence, reduced
tumour burden, less severe pulmonary adenocarcino-
mas and an age-related delay in fatal neoplastic
diseases relative to controls [92].
A comprehensive examination by two pathologists
reported that a similar percentage of Gpx4þ/2 and
control mice (55–60%) had neoplastic disease,
although an age-related delay in fatal lymphoma was
seen in Gpx4þ/2 mice [74]. Gross pathological inves-
tigation of 23- to 28-month-old PAPP-A-KO mice
revealed significantly reduced tumour burden and no
evidence of multiple tumours unlike control mice
[93]. RIIb2/2 null mice had less lymphosarcoma and
splenic tumours compared with controls, although
no differences were observed in hepatic tumours
[48]. MCAT mice had unaltered haematopoietic
tumour incidence compared with WT controls, but a
significant reduction in the severity and tumour
burden of non-haematopoietic tumours was seen
post-mortem [88]. Mice null for the pro-inflammatory
cytokine macrophage migration inhibitory factor
(MIF-KO) showed less evidence of hemangiosarcomas
compared with WT controls [94]. However, we
observed no difference in macroscopic tumour inci-
dence at death in female S6K12/2 compared with
controls [29], in agreement with findings in
bIGF1RKOþ/2 mice [18]. Lifespan extension follow-
ing rapamycin treatment in mice also did not alter the
distribution in the presumptive causes of mortality in
mice, including tumour incidence [25].(g) Youthful immune profile and reduced
inflammation in long-lived mice
The presence of a chronic inflammatory state in
humans, e.g. elevated pro-inflammatory cytokines and
local infiltration of assorted inflammatory cells,
underlies several ageing-related diseases, including
cancer [6,86]. In mice, alterations in T-cell populations
(i.e. greater proportion of naive T cells relative to
memory T cells) are predictive of both a resistance to
various cancers [95] and longevity [96,97]. However,
it should be noted that this assay may not specifically
indicate improved immune function (e.g. resistance to
infection). In addition, mouse ageing studies by their
very nature tend to use specific pathogen-free environ-
ments to protect mice from infection. Therefore, underPhil. Trans. R. Soc. B (2011)these experimental conditions, definitive measures of
improved immune function are consequently difficult
to assay. However, functional assays such as viral chal-
lenge may be useful in determining whether immune
function is maintained in long-lived mice during
ageing. Interestingly, intranasal inoculation with influ-
enza (H1N1, PR8) actually increased mortality,
increased weight loss and diminished innate immunity
in male DR mice [98].
We previously reported that female Irs12/2 mice at
450 and 700 days of age [19] and female S6K12/2
mice at 600 days of age [29] had significantly fewer
memory and more naive T cells relative to WT mice.
This is suggestive of a more youthful immune profile
in these animals. Interestingly, the age-related
reduction in haematopoietic stem cell number linked
to anaemia, impaired response to vaccination and
tumourigenesis was reversed in old mice following
rapamycin treatment [99].
Aged mice, like humans, are susceptible to several
inflammatory pathologies, including dermatitis, gastri-
tis, peritonitis and enteritis [50]. Both male and female
Irs12/2 mice were completely resistant to the age-
related ulcerative dermatitis observed in old C57BL/
6 mice, whereas 25 per cent of WT mice were afflicted
[19]. From 50 weeks of age onwards, long-lived Sp53/
Sp16/SArf/TgTert mice were protected against age-
related thinning of their epidermis and subcutaneous
fat layer [50]. These mice also had higher skin kerati-
nocyte telomerase activity, longer hair bulge and
interfollicular epidermal telomeres, and higher clono-
genic potential of epidermal stem cells at both young
and old ages [50]. Sp53/Sp16/SArf/TgTert mice also
had preserved intestinal tract epithelia during ageing
and enhanced resistance to dextran sodium sulphate-
induced intestinal ulcers [50]. PAPP-A-KO mice at
18 months of age are resistant to age-dependent
thymic atrophy, have a more youthful T-cell profile
and bone marrow enriched with thymus-seeding pro-
genitor cells compared with controls [100]. MCAT
mice also showed a trend towards less severe systemic
inflammation [88]. Aged (27–29 months) Snell
dwarfs are resistant to age-related changes in T-cell
subsets, with preservation of their immune cell func-
tion and fewer P-glycoprotein (anergic)-expressing
splenic cells [41]. However, as mentioned previously,
the relationship between immune function and
ageing appears incredibly complex. For example,
long-lived Ames dwarf mice actually show various
manifestations of immunodeficiency, in particular
those relating to thymic function [101].3. CONCLUSIONS
The application of mouse models to help inform what
mechanisms underlie healthy ageing in mammals has
provided exciting insights into this process but remains
experimentally challenging. However, it is evident that
despite these paradigm-shifting experiments, we still
have no definitive mechanistic explanation of the
ageing process, although enhanced resistance to oxi-
dative stress ([102,103] but see also [104,105]),
increased xenobiotic metabolism [106,107], altered
mitochondrial function [108,109] and enhanced
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mutually exclusive, candidate mechanisms. Ames dwarf
mice, for example, have enhanced paraquat resistance
and lower liver and lung F(2) isoprostane levels in old
age (14–20 months) compared with controls [112].
Fibroblasts from GH-deficient mice are also highly
stress resistance [113,114], with Snell dwarfs fibroblasts
showing enhanced antioxidant and base excision repair
capacity following combined serum deprivation and
paraquat exposure [115]. Therefore, we suggest that it
is critical to determine whether parameters including
stress resistance and base excision repair capacity are
also altered in an age-dependent manner in other
long-lived mouse models. Certainly, other mechanisms
are also likely to be at work and full consideration is
beyond the scope of this review, but are well covered
elsewhere (e.g [116–119]).
It is highly evident that using mammalian models to
understand what underlies extended healthy lifespan is
a rapidly expanding and competitive field of research.
This is clearly indicated by the fact that seven long-
lived genetic mouse models were described by 2003
[47] but over 20 models have been reported by 2009
[120]. The basic rationale for undertaking these
long-term, demanding and expensive studies is to
determine whether increased lifespan translates to
increased healthspan in later life. Therefore, those
studies that simultaneously measure lifespan, assay
biomarkers predictive of lifespan [121] and examine
age-related pathology are likely to be our best hope
of identifying tractable interventions that can ulti-
mately be applied to humans. In particular, we feel
that future ageing studies should pay particular
attention to late age health.
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